Moreover, since ALB has been commonly applied in clinical settings as a powerful biomaterial and therapeutic agent for the treatment of a broad range of human diseases [16,17,18,19], identification of HCC patients with poor prognosis by ALB-based biomarkers may hold great promise in selecting the patients suitable for receiving ALB-based therapeutic strategies. Here, ALB is linked to hepatocellular carcinoma.